ArticleBrain informatics2023
Explainability of random survival forests in predicting conversion risk from mild cognitive impairment to Alzheimer's disease.
Article in Brain informatics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Who Is Getting the Help They Need? An AI-Driven Study of Intersectional Disparities in Mental Health Service Utilization Among Young Adults with Suicidal Ideation.Prevention science : the official journal of the Society for Prevention Research · 2026Article
- Comparison of the Cox Proportional Hazards Model and Random Survival Forest Algorithm for Predicting Patient-Specific Survival Probabilities in Clinical Trial Data.Biometrical journal. Biometrische Zeitschrift · 2026Article
- Feature Selection Analysis and Robustness to Missing Data for Sensor-Based Prognostic Modeling of Alzheimer's Disease Progression.Sensors (Basel, Switzerland) · 2026Article
- Using radiological brain health to predict recurrence after ischemic stroke and transient ischemic attack: A population-based study.Neurology open access · 2026Article
- Unsupervised risk factor identification across cancer types and data modalities via explainable artificial intelligence.NPJ digital medicine · 2026Article
- Explainable machine-learning prediction of overall and cancer-specific survival in adult triple-negative breast cancer using SEER: a comparative study of nomograms and random survival forests.Translational cancer research · 2026Article
- In Silico Psycho-Oncology: Understanding Resilience Pathways in Breast Cancer-Determinants of Longitudinal Depression and Quality-of-Life Trajectories.Journal of personalized medicine · 2026Article
- A feature selection-based oblique hyperplane for oblique random survival forests.BMC medical research methodology · 2026Article
- Article
- Assessing the accuracy of survival machine learning and traditional statistical models for Alzheimer's disease prediction over time: a study on the ADNI cohort.BMC medical research methodology · 2025Article
- Enhancing explainability of random survival forests in predicting stent patency risk for malignant colonic obstruction.BMC gastroenterology · 2025Article
- Chorionic Gonadotropin Beta 7 is a marker of immune evasion in cancer.bioRxiv : the preprint server for biology · 2025Article
- Characterizing bidirectional transitions in mild cognitive impairment and post-reversion based on longitudinal neuroimaging and cognitive assessments.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Joint ensemble learning-based risk prediction of Alzheimer's disease among mild cognitive impairment patients.The journal of prevention of Alzheimer's disease · 2025Article
- Breaking new ground: machine learning enhances survival forecasts in hypercapnic respiratory failure.Frontiers in medicine · 2025Article
- Sex Differences in Conversion Risk from Mild Cognitive Impairment to Alzheimer's Disease: An Explainable Machine Learning Study with Random Survival Forests and SHAP.Brain sciences · 2024Article
- Long-term Alzheimer's disease mortality prediction in adults aged ≥60 years: A prospective cohort study benchmarking survival machine learning algorithms.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Random Survival Forests (RSF) has recently showed better performance than statistical survival methods as Cox proportional hazard (CPH) in predicting conversion risk from mild cognitive impairment (MCI) to Alzheimer's disease (AD). However, RSF application in real-world clinical setting is still limited due to its black-box nature.For this reason, we aimed at providing a comprehensive study of RSF explainability with SHapley Additive exPlanations (SHAP) on biomarkers of stable and progressive patients (sMCI and pMCI) from Alzheimer's Disease Neuroimaging Initiative. We evaluated three global explanations-RSF feature importance, permutation importance and SHAP importance-and we quantitatively compared them with Rank-Biased Overlap (RBO). Moreover, we assessed whether multicollinearity among variables may perturb SHAP outcome. Lastly, we stratified pMCI test patients in high, medium and low risk grade, to investigate individual SHAP explanation of one pMCI patient per risk group.We confirmed that RSF had higher accuracy (0.890) than CPH (0.819), and its stability and robustness was demonstrated by high overlap (RBO > 90%) between feature rankings within first eight features. SHAP local explanations with and without correlated variables had no substantial difference, showing that multicollinearity did not alter the model. FDG, ABETA42 and HCI were the first important features in global explanations, with the highest contribution also in local explanation. FAQ, mPACCdigit, mPACCtrailsB and RAVLT immediate had the highest influence among all clinical and neuropsychological assessments in increasing progression risk, as particularly evident in pMCI patients' individual explanation. In conclusion, our findings suggest that RSF represents a useful tool to support clinicians in estimating conversion-to-AD risk and that SHAP explainer boosts its clinical utility with intelligible and interpretable individual outcomes that highlights key features associated with AD prognosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.